42701 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Sep 23
00:12 UTC
|
ELD
Eldorado Gold
|
◎ Target | firm only | C$55.00→ C$63.00+14.5% | |
|
Sep 23
00:12 UTC
|
EFX
Equifax
|
◎ Target | Jason Haas not yet tracked | Overweight | $212.00→ $200.00-5.7% |
|
Sep 23
00:12 UTC
|
DHT.UN
DRI Healthcare Trust
|
◎ Target | firm only | Outperform | C$23.50→ C$25.50+8.5% |
|
Sep 23
00:12 UTC
|
DHI
D.R. Horton
|
◎ Target | Jade Rahmani ★★★☆☆ #1035 | Market Perform | $167.00→ $160.00-4.2% |
|
Sep 23
00:12 UTC
|
DAVA
Endava
|
◎ Target | Nate Svensson ★★★★★ #179 | Hold | $3.00→ $2.00-33.3% |
|
Sep 23
00:12 UTC
|
DAR
Darling Ingredients
|
◎ Target | Manav Gupta ★★★★☆ #812 | Buy | $78.00→ $88.00+12.8% |
|
Sep 23
00:12 UTC
|
CU
Canadian Utilities
|
◎ Target | firm only | C$55.00→ C$52.00-5.5% | |
|
Sep 23
00:12 UTC
|
CSCO
Cisco Systems
|
◎ Target | James Fish ★★★☆☆ #1143 | Neutral | $132.00→ $125.00-5.3% |
|
Sep 23
00:12 UTC
|
CRH
CRH
|
◎ Target | Julian Radlinger ★★★☆☆ #1200 | Buy | $147.00→ $135.00-8.2% |
|
Sep 23
00:12 UTC
|
CPX
Capital Power
|
◎ Target | firm only | C$83.00→ C$80.00-3.6% | |
|
Sep 23
00:12 UTC
|
COLB
Columbia Banking System
|
◎ Target | Benjamin Gerlinger not yet tracked | Neutral | $32.00→ $31.00-3.1% |
|
Sep 23
00:12 UTC
|
CNTB
Connect Biopharma
|
◎ Target | Mazahir Alimohamed not yet tracked | Outperform | $5.00 |
|
Sep 23
00:12 UTC
|
CLDX
Celldex Therapeutics
|
◎ Target | Joseph Pantginis ★★☆☆☆ #2593 | Buy | $42.00→ $64.00+52.4% |
|
Sep 23
00:12 UTC
|
CLDX
Celldex Therapeutics
|
◎ Target | Kristen Kluska ★★★☆☆ #1610 | Overweight | $61.00→ $72.00+18.0% |
|
Sep 23
00:12 UTC
|
CHRD
Chord Energy
|
◎ Target | Josh Silverstein ★★☆☆☆ #2624 | Buy | $189.00→ $184.00-2.6% |
|
Sep 23
00:12 UTC
|
CCL
Carnival
|
◎ Target | Kevin Kopelman ★★★☆☆ #1495 | Buy | $34.00→ $32.00-5.9% |
|
Sep 23
00:12 UTC
|
BPOP
Popular
|
◎ Target | Benjamin Gerlinger not yet tracked | Buy | $200.00→ $192.00-4.0% |
|
Sep 23
00:12 UTC
|
BOOT
Henry Boot
|
◎ Target | firm only | Buy | GBX 219→ GBX 186-15.1% |
|
Sep 23
00:12 UTC
|
BMNR
BitMine Immersion Technologies
|
◎ Target | Fedor Shabalin ★★★☆☆ #1703 | Buy | $30.00→ $34.00+13.3% |
|
Sep 23
00:12 UTC
|
AXS
Accsys Technologies
|
◎ Target | firm only | Buy | GBX 130→ GBX 120-7.7% |
|
Sep 23
00:12 UTC
|
ASST
Strive
|
◎ Target | Fedor Shabalin ★★★☆☆ #1703 | Buy | $26.00→ $33.00+26.9% |
|
Sep 23
00:12 UTC
|
AQN
Algonquin Power & Utilities
|
◎ Target | firm only | C$6.25→ C$6.00-4.0% | |
|
Sep 23
00:12 UTC
|
APH
Amphenol
|
◎ Target | Andrew Buscaglia ★★☆☆☆ #2643 | Outperform | $107.50→ $110.00+2.3% |
|
Sep 23
00:12 UTC
|
ANIX
Anixa Biosciences
|
◎ Target | Yi Chen ★★★☆☆ #1641 | Buy | $7.00→ $6.00-14.3% |
|
Sep 23
00:12 UTC
|
AMRZ
Amrize
|
◎ Target | Julian Radlinger ★★★☆☆ #1200 | Neutral | $57.00→ $42.00-26.3% |
|
Sep 23
00:12 UTC
|
ALKS
Alkermes
|
◎ Target | Joel Beatty ★☆☆☆☆ #2923 | Outperform | $58.00→ $61.00+5.2% |
|
Sep 23
00:12 UTC
|
ADPT
Adaptive Biotechnologies
|
◎ Target | Mark Massaro ★★★★☆ #715 | Buy | $25.00→ $34.00+36.0% |
|
Sep 23
00:12 UTC
|
ACO.X
ATCO
|
◎ Target | firm only | C$88.00→ C$85.00-3.4% | |
|
Sep 23
00:12 UTC
|
ABVX
Abivax
|
◎ Target | Gregory Renza ★★☆☆☆ #2794 | Buy | $155.00→ $151.00-2.6% |
|
Sep 23
00:12 UTC
|
ABVX
Abivax
|
◎ Target | David Nierengarten ★★★☆☆ #2221 | Neutral | $140.00→ $118.00-15.7% |
|
Sep 23
00:12 UTC
|
AA
Alcoa
|
◎ Target | Vitaly Kononov ★★★★☆ #562 | Buy | $64.00→ $76.00+18.8% |
|
Sep 23
00:12 UTC
|
REPYY
Repsol
|
↓ Downgrade | firm only | Outperform→ Neutral | |
|
Sep 23
00:12 UTC
|
NFLX
Netflix
|
↓ Downgrade | Mohammed Khallouf ★★☆☆☆ #2268 | Buy→ Hold | $96.00→ $76.00-20.8% |
|
Sep 23
00:12 UTC
|
EXK
Endeavour Silver
|
↓ Downgrade | firm only | Outperform→ Neutral | |
|
Sep 23
00:12 UTC
|
ERIC
Ericsson
|
↓ Downgrade | Terrance Tsul not yet tracked | Equal Weight→ Underweight | $11.00→ $9.00-18.2% |
|
Sep 23
00:12 UTC
|
DAVA
Endava
|
↓ Downgrade | Maggie Nolan ★★★☆☆ #1765 | Market Perform→ Underperform | |
|
Sep 23
00:12 UTC
|
CMPX
Compass Therapeutics
|
↓ Downgrade | Robert Driscoll ★★★☆☆ #1041 | Neutral | $1.00 |
|
Sep 23
00:12 UTC
|
BRBY
Burberry Group
|
↓ Downgrade | firm only | Sec→ r perform | GBX 1,400→ GBX 1,200-14.3% |
|
Sep 23
00:12 UTC
|
BEAT
HeartBeam
|
↓ Downgrade | Yi Chen ★★★☆☆ #1641 | Buy→ Neutral | |
|
Sep 23
00:12 UTC
|
BCAX
Bicara Therapeutics
|
↓ Downgrade | firm only | Equal Weight | |
|
Sep 23
00:12 UTC
|
WST
West Pharmaceutical Services
|
↑ Upgrade | Kallum Titchmarsh ★★★☆☆ #1834 | Equal Weight→ Overweight | $365.00→ $400.00+9.6% |
|
Sep 23
00:12 UTC
|
VLEEY
Valeo
|
↑ Upgrade | firm only | Hold→ Buy | |
|
Sep 23
00:12 UTC
|
RNR
RenaissanceRe
|
↑ Upgrade | firm only | Hold→ Market Outperform | |
|
Sep 23
00:12 UTC
|
QNCX
Quince Therapeutics
|
↑ Upgrade | Jonathan Wolleben ★★★★★ #283 | Market Perform→ Outperform | $77.00 |
|
Sep 23
00:12 UTC
|
QNCX
Quince Therapeutics
|
↑ Upgrade | firm only | Market Perform→ Outperform | |
|
Sep 23
00:12 UTC
|
OMER
Omeros
|
↑ Upgrade | Olivia Brayer Saunders not yet tracked | Neutral→ Overweight | $22.00 |
|
Sep 23
00:12 UTC
|
MET
MetLife
|
↑ Upgrade | Paul Newsome ★★★☆☆ #1588 | Neutral→ Overweight | $99.00→ $110.00+11.1% |
|
Sep 23
00:12 UTC
|
HFWA
Heritage Financial
|
↑ Upgrade | firm only | Neutral→ Buy | $33.00 |
|
Sep 23
00:12 UTC
|
FITB
Fifth Third Bancorp
|
↑ Upgrade | Benjamin Gerlinger not yet tracked | Neutral→ Buy | $59.00→ $62.00+5.1% |
|
Sep 23
00:12 UTC
|
EPM
Evolution Petroleum
|
↑ Upgrade | Sergey Pigarev ★★★★☆ #419 | Hold→ Buy | $4.50 |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.